BRPI0512645A - processos para a determinação da potência, da especificidade e da toxicidade da prostaglandina d2 sintase hematopoiética - Google Patents

processos para a determinação da potência, da especificidade e da toxicidade da prostaglandina d2 sintase hematopoiética

Info

Publication number
BRPI0512645A
BRPI0512645A BRPI0512645-2A BRPI0512645A BRPI0512645A BR PI0512645 A BRPI0512645 A BR PI0512645A BR PI0512645 A BRPI0512645 A BR PI0512645A BR PI0512645 A BRPI0512645 A BR PI0512645A
Authority
BR
Brazil
Prior art keywords
synthase
potency
specificity
toxicity
procedures
Prior art date
Application number
BRPI0512645-2A
Other languages
English (en)
Inventor
Yang Cao
Jeffrey S Sabol
Stephen Ayers
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of BRPI0512645A publication Critical patent/BRPI0512645A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/533—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving isomerase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/88—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving prostaglandins or their receptors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Ecology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

PROCESSOS PARA A DETERMINAçãO DA POTêNCIA, DA ESPECIFICIDADE E DA TOXICIDADE DA PROSTAGLANDINA D2 SINTASE HEMATOPOIéTICA. A presente invenção refere-se a um processo novo e útil para a dosagem de compostos e de agentes por sua capacidade de diminuir ou de inibir a atividade da prostaglandina D2 sintase hematopolética (hPGDS). Especificamente, a presente invenção refere-se a dosagens para a medida da potência, da especificidade e da toxicidade dos inibidores de hPGDS.
BRPI0512645-2A 2004-07-30 2005-07-28 processos para a determinação da potência, da especificidade e da toxicidade da prostaglandina d2 sintase hematopoiética BRPI0512645A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59250104P 2004-07-30 2004-07-30
PCT/US2005/026945 WO2006015195A1 (en) 2004-07-30 2005-07-28 Methods for determining the potency, specificity, and toxicity of hematopoietic prostaglandin d2 synthase

Publications (1)

Publication Number Publication Date
BRPI0512645A true BRPI0512645A (pt) 2008-03-25

Family

ID=35115717

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0512645-2A BRPI0512645A (pt) 2004-07-30 2005-07-28 processos para a determinação da potência, da especificidade e da toxicidade da prostaglandina d2 sintase hematopoiética

Country Status (15)

Country Link
US (1) US20070259384A1 (pt)
EP (1) EP1778860B1 (pt)
JP (1) JP2008507980A (pt)
KR (1) KR20070046830A (pt)
CN (1) CN1993479A (pt)
AT (1) ATE384136T1 (pt)
AU (1) AU2005267920A1 (pt)
BR (1) BRPI0512645A (pt)
CA (1) CA2575523A1 (pt)
DE (1) DE602005004420T2 (pt)
DK (1) DK1778860T3 (pt)
ES (1) ES2297753T3 (pt)
IL (1) IL180837A0 (pt)
MX (1) MX2007000043A (pt)
WO (1) WO2006015195A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009246446B2 (en) 2008-05-13 2014-06-26 Cayman Chemical Company, Incorporated Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase
CN111549000B (zh) * 2020-06-18 2022-07-29 中国医学科学院整形外科医院 一种过表达Hpgds的重组脂肪干细胞、制备方法及其应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3600847B2 (ja) * 1996-06-05 2004-12-15 財団法人大阪バイオサイエンス研究所 ヒトの造血器型プロスタグランジンｄ合成酵素をコードするｄｎａ
GB0229244D0 (en) * 2002-08-16 2003-01-22 Aventis Pharma Inc Method for assaying compounds for inhibition of the activity of prostaglandin synthase
WO2004031180A1 (ja) * 2002-10-03 2004-04-15 Institute Of Medicinal Molecular Design. Inc. キナゾリン−４−オン誘導体

Also Published As

Publication number Publication date
DE602005004420T2 (de) 2009-01-08
ATE384136T1 (de) 2008-02-15
US20070259384A1 (en) 2007-11-08
JP2008507980A (ja) 2008-03-21
DK1778860T3 (da) 2008-05-13
CA2575523A1 (en) 2006-02-09
MX2007000043A (es) 2007-03-27
WO2006015195A8 (en) 2006-12-21
CN1993479A (zh) 2007-07-04
ES2297753T3 (es) 2008-05-01
DE602005004420D1 (de) 2008-03-06
EP1778860B1 (en) 2008-01-16
EP1778860A1 (en) 2007-05-02
IL180837A0 (en) 2007-06-03
AU2005267920A1 (en) 2006-02-09
WO2006015195A1 (en) 2006-02-09
KR20070046830A (ko) 2007-05-03

Similar Documents

Publication Publication Date Title
CR11618A (es) Inhibidores macrocíclicos de serina proteasa
EA200701257A1 (ru) Пирролопиразолы в качестве сильнодействующих ингибиторов киназы
SV2006002232A (es) Inhibidores bace ref. x-16940
BRPI0513897A (pt) diferenciação de células-tronco
UY29479A1 (es) Inhibidores de adn-pk
DOP2010000191A (es) Derivados bis-(sulfonilamino)
DK1761520T3 (da) Kinaseinhibitorer
CY1106132T1 (el) Παραγωγα πιπepιδινης ως αναστολεις καναλιου καλιου
NO20080761L (no) Acykliske Ikur inhibitorer
NO20071309L (no) Fremgangsmate for ekspansjon
MY144590A (en) Glutamate aggrecanase inhibitors
NO20062649L (no) Biarylsulfonamider og metoder for anvendelse av disse
CY1109911T1 (el) Πυρρολοβενζοδιαζεπινες
PA8667201A1 (es) Nuevos compuestos farmaceuticos
RS52799B (en) DIHYDROGEN PHOSPHATE ARE PROSTAGLAND D2 RECEPTOR ANTAGONISTS
MX2010003259A (es) Ensayo de monitoreo de farmacos.
HN2006019513A (es) Inhibidores de la fosfolipasa a2 citosolica
SV2006002001A (es) Inhibidores de quinasa ref. x - 16437
CL2012003104A1 (es) Compuestos derivados de multiheteroarilos, inhibidores de prostaglandina d sintasa hematopoyetica (h-pgds); y composicion farmaceutica que los comprende.
DE112005003431A5 (de) Neuartige Inhibitoren der Lysyloxidase
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
MY146805A (en) 2-(substituted-amino)-benzothiazole sulfonamide hiv protease inhibitors
DE502006008710D1 (de) Substituierte tetrahydroisochinoline als mmp-inhibitoren, verfahren zu ihrer herstellung und ihre verwendung als medikament
DE60336475D1 (de) Ät
BRPI0512645A (pt) processos para a determinação da potência, da especificidade e da toxicidade da prostaglandina d2 sintase hematopoiética

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: AVENTIS PHARMACEUTICALS, INC. (US)

Free format text: SEDE ALTERADA CONFORME SOLICITADO NA PETICAO NO 020070165509/RJ DE 23/11/2007.

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A E 6A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2158 DE 15/05/2012.